Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial

Wheeler, 2020, SGLT2 inhibitors: slowing of chronic kidney disease progression in type 2 diabetes, Diabetes Ther, 11, 2757, 10.1007/s13300-020-00930-x Neal, 2017, Canagliflozin and cardiovascular and renal events in type 2 diabetes, N Engl J Med, 377, 644, 10.1056/NEJMoa1611925 Wanner, 2016, Empagliflozin and progression of kidney disease in type 2 diabetes, N Engl J Med, 375, 323, 10.1056/NEJMoa1515920 Cherney, 2014, Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus, Circulation, 129, 587, 10.1161/CIRCULATIONAHA.113.005081 Cherney, 2020, Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial, Lancet Diabetes Endocrinol, 8, 582, 10.1016/S2213-8587(20)30162-5 Heerspink, 2016, Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications, Circulation, 134, 752, 10.1161/CIRCULATIONAHA.116.021887 van Bommel, 2020, The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial, Kidney Int, 97, 202, 10.1016/j.kint.2019.09.013 1997, Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy, Lancet, 349, 1857, 10.1016/S0140-6736(96)11445-8 Maschio, 1996, Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency, N Engl J Med, 334, 939, 10.1056/NEJM199604113341502 Hou, 2006, Efficacy and safety of benazepril for advanced chronic renal insufficiency, N Engl J Med, 354, 131, 10.1056/NEJMoa053107 Brenner, 2001, Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, N Engl J Med, 345, 861, 10.1056/NEJMoa011161 Heerspink, 2020, Dapagliflozin in patients with chronic kidney disease, N Engl J Med, 383, 1436, 10.1056/NEJMoa2024816 Heerspink, 2020, Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial, Nephrol Dial Transplant, 35, 274, 10.1093/ndt/gfz290 Wheeler, 2020, The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics, Nephrol Dial Transplant, 35, 1700, 10.1093/ndt/gfaa234 Packer, 2020, Cardioprotective effects of sirtuin-1 and its downstream effectors potential role in mediating the heart failure benefits of SGLT2 (sodium-glucose cotransporter 2) inhibitors, Circ Heart Fail, 10.1161/CIRCHEARTFAILURE.120.007197 Marton, 2020, Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation, Nat Rev Nephrol Dekkers, 2018, Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers, Diabetes Obes Metab, 20, 1988, 10.1111/dom.13301 Woods, 2019, Canagliflozin prevents intrarenal angiotensinogen augmentation and mitigates kidney injury and hypertension in mouse model of type 2 diabetes mellitus, Am J Nephrol, 49, 331, 10.1159/000499597 McMurray, 2019, Dapagliflozin in patients with heart failure and reduced ejection fraction, N Engl J Med, 381, 1995, 10.1056/NEJMoa1911303 Petrie, 2020, Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes, JAMA, 323, 1353, 10.1001/jama.2020.1906 Jhund, 2020, Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF, Circulation Packer, 2020, Cardiovascular and renal outcomes with empagliflozin in heart failure, N Engl J Med, 383, 1413, 10.1056/NEJMoa2022190 Herrington, 2018, The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study, Clin Kidney J, 11, 749, 10.1093/ckj/sfy090 2011 Fioretto, 2018, Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): the DERIVE study, Diabetes Obes Metab, 20, 2532, 10.1111/dom.13413 Pollock, 2019, Lancet Diabetes Endocrinol, 7, 429, 10.1016/S2213-8587(19)30086-5